AstraZeneca COVID-19 Vaccine Shows 74% Efficacy in U.S. Trial By Reuters AstraZeneca Plc’s (AZN.L) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65 October 1, 2021 News·TL
